Phase 3 Randomized, Double-Blind Study of Ianalumab and Eltrombopag Versus Placebo in Primary Immune Thrombocytopenia Post-Steroid Treatment Failure

No specific information regarding the primary or secondary objectives of the study is available. Additionally, details about the medical condition being studied, the full or public title of the trial, and the products involved are not provided.

The sponsor does not provide information regarding the participants of the clinical trial, including the **study population** characteristics such as age range, gender, and general health status. Additionally, details about the total number of participants, selection criteria, lifestyle considerations, and any key inclusion or exclusion criteria are not disclosed.

The clinical trial is designed to evaluate the efficacy and safety of a new therapeutic intervention. The study employs a **randomized**, **double-blind**, and **controlled** trial design to ensure the reliability and validity of the results. Participants will be randomly assigned to either the treatment group or the control group, with neither the participants nor the investigators aware of the group assignments, thus maintaining the integrity of the blinding process. The overall duration of the trial is anticipated to span several months, with specific timelines dependent on the recruitment and retention of participants.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants are assessed against the inclusion and exclusion criteria to determine eligibility for the trial. Following successful enrollment, participants will attend a series of follow-up visits at predetermined intervals. These visits are crucial for monitoring the participants' health status, adherence to the study protocol, and any adverse events that may occur. The end-of-study visit marks the conclusion of the participant's involvement in the trial, during which final assessments are conducted to gather comprehensive data on the intervention's outcomes.

Participant involvement is expected to last for the entire duration of the trial, from the initial screening to the end-of-study visit. However, certain conditions may necessitate early termination from the study, such as the occurrence of serious adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical guidelines and regulatory requirements, ensuring the safety and well-being of all participants throughout the study period.

There is no available data regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration. Additionally, information about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not provided. Details concerning drug administration, dosing schedules, and participant compliance monitoring are also absent. Consequently, a comprehensive description of the treatments used in this clinical trial cannot be constructed based on the provided data.

No information is available to provide a description of how efficacy will be assessed in the clinical trial.